Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ABOS, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Sabirnetug | Alzheimer Disease | Phase 2 · NCT06335173 | Active not recruiting |
| ACU193 | Alzheimer Disease | Phase 1 · NCT04931459 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ABOS holds $110.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $21.1M/quarter from operations, an estimated runway of 15.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 65 · High
Accordingly, the Company has concluded that substantial doubt exists about its ability to continue as a going concern.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ABOS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| James B. Murray Jr. | 5%+ holder (13G) | 3,611,360 | 4.99% | 2025-04-04 |
| Daniel Joseph OConnell Chief Executive Officer, Director · +450,000 options |
Insider | 881,275 | 1.22% | 2026-01-21 |
| RA CAPITAL MANAGEMENT, L.P. Director, 10% owner · +72,750 options |
Insider | 588,850 | 0.81% | 2026-06-03 |
| Matt Zuga CFO & Chief Business Officer · +148,700 options |
Insider | 304,924 | 0.42% | 2026-01-21 |
| Eric Siemers Chief Medical Officer · +148,700 options |
Insider | 255,371 | 0.35% | 2026-01-21 |
| James J. Doherty President and CDO · +250,300 options |
Insider | 220,900 | 0.31% | 2026-01-16 |
| John A III Stalfort Director · +53,250 options |
Insider | 220,624 | 0.31% | 2026-06-03 |
| Russell Barton Chief Operating Officer · +126,900 options |
Insider | 205,092 | 0.28% | 2026-01-21 |
| Derek M Meisner Chief Legal Officer & Corp Sec · +219,748 options |
Insider | 173,999 | 0.24% | 2026-03-06 |
| Amy Schacterle Chief Regulatory Officer · +126,900 options |
Insider | 92,303 | 0.13% | 2026-01-16 |
| Kimberlee C Drapkin Director · +53,250 options |
Insider | 48,300 | 0.07% | 2026-06-03 |
| Laura Stoppel Director · +53,250 options |
Insider | 48,300 | 0.07% | 2026-06-03 |
Share count 72,317,285 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABOS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →